A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo

作者：Boucherle Benjamin; Bertrand Johanna; Maurin Bruno; Renard Brice Loic; Fortune Antoine; Tremblier Brice; Becq Frederic; Norez Caroline; Decout Jean Luc^*

来源：European Journal of Medicinal Chemistry, 2014, 83: 455-465.

DOI：10.1016/j.ejmech.2014.06.028

• Cystic fibrosis
• F508del-CFTR
• Modulators
• Activators
• Salivary secretion
• Docking
• Nucleotide binding domains

Cystic fibrosis transmembrane conductance regulator (CFTR) is the main chloride channel present in the apical membrane of epithelial cells and the F508 deletion (F508del-CFTR) in the CF gene is the most common cystic fibrosis-causing mutation. In the search for a pharmacotherapy of cystic fibrosis caused by the F508del-CFTR, a bi-therapy could be developed associating a corrector of F508del-CFTR trafficking and an activator of the channel activity of CFTR. Here, we report on the synthesis of 9-alkcyladenine derivatives analogues of our previously discovered activator of wt-CFTR and F508del-CHR, GPact-11a, and the identification of a new activator of these channels, GPact-26a, through various flux assays on human airway epithelial CF and non-CF cell lines and in vivo measurement of rat salivary secretion. This study reveals that the possible modifications of the side chain introduced at the NO position of the main pharmacophore are highly limited since only an allyl group can replace the propyl side chain present in GPact-11a to lead to a strong activation of wt-CFTR in CHO cells. Docking simulations of the synthesised compounds and of four described modulators performed using a 3D model of the wt-type CFTR protein suggest five possible binding sites located at the interface of the nucleotide binding domains NBD1/NBD2. However, the docking study did not allow the differentiation between active and non-active compounds.

• 出版日期2014-8-18